Anti-TGF-beta antibodies and their use
US12049496B2 · kind B2 · utility
0Cited by
19References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2021 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Nov 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.